Champions Oncology, Inc. (CSBR)
| Market Cap | 81.93M |
| Revenue (ttm) | 57.95M |
| Net Income (ttm) | -2.34M |
| Shares Out | 13.89M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,395 |
| Open | 6.16 |
| Previous Close | 6.02 |
| Day's Range | 5.70 - 6.32 |
| 52-Week Range | 5.50 - 9.63 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 12, 2026 |
About CSBR
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers... [Read more]
Financial Performance
Financial StatementsNews
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions ...
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology, Inc. (Nasd...
Champions Oncology Earnings Call Transcript: Q3 2026
Record core study revenue and positive adjusted EBITDA offset a year-over-year revenue decline due to the absence of data revenue. Early traction in the data business and continued investment in growth initiatives position the company for stronger results in fiscal 2027.
Champions Oncology Reports Revenue of $16.6 Million
Company remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / March 12, 2026 / Champions Oncology, Inc. (Nasdaq:...
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
HACKENSACK, NJ / ACCESS Newswire / March 5, 2026 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the th...
Champions Oncology Earnings Call Transcript: Q2 2026
Revenue grew 11% year-over-year to $15M, with gross margin rising to 52% and adjusted EBITDA at $800K. Strategic investments in radiolabeling and data platforms are driving growth, while the company remains on track for full-year positive adjusted EBITDA.
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK, NJ / ACCESS Newswire / December 15, 2025 / Champions Oncology, Inc....
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the...
CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million
This release contains a headline correction from the previous publication. Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15...
Champions Oncology Earnings Call Transcript: Q1 2026
Q1 revenue rebounded to $14 million, with stability year-over-year and growth in the TOS and data businesses. Gross margin declined to 43% due to higher outsourced costs, but margin expansion is expected as work shifts in-house. Management projects sequential revenue growth and a strong cash position.
Champions Oncology Reports Record Quarterly Revenue of $14.0 Million
Positive start to FY 2026 with steady revenue, data growth and new leadership HACKENSACK, NJ / ACCESS Newswire / September 15, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational on...
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, ...
Champions Oncology Earnings Call Transcript: Q4 2025
Fiscal 2025 saw record revenue, a return to profitability, and margin expansion, driven by growth in core services and new data licensing deals. The launch of radiopharmaceutical services and a strong cash position support a positive outlook, despite ongoing market headwinds.
Champions Oncology Reports Record Annual Revenue of $57 Million
Total annual revenue growth of 14% HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced it...
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
HACKENSACK, NJ / ACCESS Newswire / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report ...
Champions Oncology Announces Appointment of New CEO
HACKENSACK, NJ / ACCESS Newswire / July 18, 2025 / Champions Oncology (NASDAQ:CSBR), a leading provider of oncology-focused CRO services specializing in preclinical and clinical specialty testing, tod...
Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models
Expanded offering delivers integrated radiopharmaceutical studies using clinically relevant isotopes and highly characterized PDX tumor models HACKENSACK, NJ / ACCESS Newswire / July 8, 2025 / Champio...
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinica...
Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine
HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of t...
Champions Oncology Earnings Call Transcript: Q3 2025
Record Q3 revenue and profitability were driven by core services and the first data licensing deal, with strong gross margins and operational efficiencies. The company is expanding its data platform and expects long-term growth, though near-term volatility and industry headwinds persist.
Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million
HACKENSACK, NJ / ACCESS Newswire / March 11, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, toda...
Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025
HACKENSACK, NJ / ACCESS Newswire / March 6, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will ...
Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting
HACKENSACK, NJ / ACCESS Newswire / February 18, 2025 / Champions Oncology Inc. (NASDAQ:CSBR), a global leader in preclinical oncology research and clinical specialty testing, today announced the accep...
Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership
HACKENSACK, NJ / ACCESSWIRE / January 8, 2025 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading technology-enabled oncology research organization with specialty testing services, is excited to annou...
Champions Oncology Earnings Call Transcript: Q2 2025
Q2 delivered strong financial results with 17% revenue growth and improved margins, driven by core services and operational efficiencies. A new data licensing revenue stream is set to launch, and the funding environment is showing signs of recovery.